||| FROM BRUCE BENTON |||


Merck & Co. donated newly-discovered Ivermectin to treat all impacted by onchocerciasis (riverblindness) while I was Manager of the World Bank/World Health Organization effort to control the disease throughout Africa. It was a game-changer. Ivermectin has proven pivotal in the near-elimination of onchocerciasis Africa-wide where 99.6% of the world’s cases of the disease occur. It’s been a major success in global health, surpassed only by smallpox and polio eradication. More than 200 million of the absolute poor living in remote rural areas throughout the continent are now protected from unbearable, incessant itching and irreversible blindness in the prime of life.

The Ivermectin story is covered in my recent book, Riverblindness in Africa – Taming the Lion’s Stare (Johns Hopkins University Press, 2020). The drug became known as the “miracle molecule” – safe with a broad spectrum of activity against parasitic infections. It showed effectiveness against onchocerciasis, lymphatic filariasis, intestinal worms, head lice, and scabies. The impact of Ivermectin on human health, particularly in the developing world, has been dramatic, resulting in the Nobel Prize in Medicine awarded for its discovery, jointly to Merck’s Bill Campbell and the Kitasato Institute’s Satoshi Omura in 2015.

Ivermectin is now being touted by some for Covid-19. Why Covid-19, which is a viral not a parasitic infection? The interest in Ivermectin as a Covid-19 drug began in March 2020 when Australian scientists found that the drug inhibited replication of SARS-CoV-2 in a laboratory petri dish. But the dosage was at a concentration up to 2000 times higher than the standard Ivermectin dosage for treating parasitic infections in humans. After seeing those results, I contacted colleagues at Merck about prospects for treating Covid-19 with Ivermectin. Their view was that the toxic effects from the high doses required precluded its use against Covid-19.

A number of studies followed over the next 18 months. Most were too small to derive definitive conclusions. Three of the largest studies citing effectiveness against Covid-19 had serious flaws. One from Egypt failed to publish underlying data, included plagiarisms, and was eventually withdrawn. Another from Argentina, that showed 100% protection against Covid-19, is suspected of fabricated data; and one of the hospitals purportedly hosting the study denied it took place there.

Most recently, two large-scale randomized controlled studies – the gold standard in clinical trials – have shown Ivermectin to be ineffective against Covid-19. One of these, led by Ed Mills of McMaster University – which is larger than all other Ivermectin/Covid studies combined – concludes that Ivermectin has “no important clinical benefit” against Covid-19. Currently, all major reputable health organizations, i.e., CDC, NIH, FDA, WHO, and the Infectious Diseases Society of America, oppose using Ivermectin to treat or prevent Covid-19.

Despite the solid evidence, a number of sources continue to push Ivermectin as a treatment for Covid-19. Consequently, there has been a dramatic increase in Ivermectin prescriptions and overdoses that caused two deaths this past September. Overdoses have been worse because people are resorting to highly-concentrated Ivermectin for large animals.

Why am I concerned? I am concerned that the dangerous use of Ivermectin as a false Covid-19 treatment, will negatively impact the legitimate and critical use of this drug to alleviate suffering for tens of millions of the poorest of the poor. This would be a tragedy. I am also concerned that the false belief that Ivermectin is effective against Covid-19 has become a major disincentive to getting vaccinated – even though vaccinations are free and have undergone the most intense safety monitoring in US history. That disincentive inhibits achieving herd immunity, which this country desperately needs to return to some semblance of pre-pandemic normality.

Bruce Benton, Orcas Island resident, is a former World Bank Manager of the Riverblindness (Onchocerciasis) Control Program for Africa, former Assistant Professor for Global Health at Georgetown University, and author of Riverblindness in Africa: Taming the Lion’s Stare (Johns Hopkins University Press, December 2020)


 

**If you are reading theOrcasonian for free, thank your fellow islanders. If you would like to support theOrcasonian CLICK HERE to set your modestly-priced, voluntary subscription. Otherwise, no worries; we’re happy to share with you.**